This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Reply to Letter to the Editor "Problems With Ensuring a Double Blind"

Raffaella Zanardi, David Rossini, and Alessandro Serretti

Published: April 1, 2001

Article Abstract

Letter to the Editor

Sir: Drs. Kumar and Oakley-Browne raised 2 concerns about our study design. The first is related to the possibility of breaking the blind of the study given the different side effect profiles of fluvoxamine and venlafaxine, since the 2 drugs have different mechanisms of action. To address this observation, we point out the following considerations: Firstly, even if the 2 drugs belong to different classes of antidepressants, it should be noted that venlafaxine is a serotonin-norepinephrine reuptake inhibitor, thus sharing with fluvoxamine the action on serotonin reuptake.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 62

Quick Links: